諾和諾德聘請美國製藥業資深人士，應對特朗普施加的定價壓力

路透中文

10/17

<a href="https://laohu8.com/S/NVO">諾和諾德</a>聘請美國製藥業資深人士，應對特朗普施加的定價壓力

路透社倫敦/哥本哈根10月17日 - 諾和諾德NOVOb.CO在LinkedIn上發表聲明稱，已任命美國製藥業高管格雷格-麥利（Greg Miley）為其新任企業事務主管，因為這家肥胖症製藥商在藥品定價方面面臨着來自特朗普政府越來越大的壓力。

美國人麥利目前是美國製藥巨頭艾伯維公司（AbbVie ABBV.N）負責政府事務的高級副總裁。他週五在LinkedIn上發佈了這一聲明，諾和諾德公司與路透社分享了這一聲明。

(為便利非英文母語者，路透將其報導自動化翻譯為數種其他語言。由於自動化翻譯可能有誤，或未能包含所需語境，路透不保證自動化翻譯文本的準確性，僅是為了便利讀者而提供自動化翻譯。對於因為使用自動化翻譯功能而造成的任何損害或損失，路透不承擔任何責任。)

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2576679051"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2576679051\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2576679051?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-10-17 22:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2576679051","market":"us","top_or_hot":-1,"title":"諾和諾德聘請美國製藥業資深人士，應對特朗普施加的定價壓力","media":"路透中文","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/NVO\">諾和諾德</a>聘請美國製藥業資深人士，應對特朗普施加的定價壓力</title></head><body><p><span>路透社倫敦/哥本哈根10月17日</span><span> - </span>諾和諾德<span>NOVOb.CO</span>在LinkedIn上發表聲明稱，已任命美國製藥業高管格雷格-麥利（Greg Miley）為其新任企業事務主管，因為這家肥胖症製藥商在藥品定價方面面臨着來自特朗普政府越來越大的壓力。</p><p>美國人麥利目前是美國製藥巨頭<a href=\"https://laohu8.com/S/ABBV\">艾伯維公司</a>（AbbVie <span>ABBV.N</span>）負責政府事務的高級副總裁。他週五在LinkedIn上發佈了這一聲明，諾和諾德公司與路透社分享了這一聲明。</p><p>(為便利非英文母語者，路透將其報導自動化翻譯為數種其他語言。由於自動化翻譯可能有誤，或未能包含所需語境，路透不保證自動化翻譯文本的準確性，僅是為了便利讀者而提供自動化翻譯。對於因為使用自動化翻譯功能而造成的任何損害或損失，路透不承擔任何責任。)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>諾和諾德聘請美國製藥業資深人士，應對特朗普施加的定價壓力</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n諾和諾德聘請美國製藥業資深人士，應對特朗普施加的定價壓力\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1098195322\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">路透中文 </p>\n<p class=\"h-time smaller\">2025-10-17 22:47</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/NVO\">諾和諾德</a>聘請美國製藥業資深人士，應對特朗普施加的定價壓力</title></head><body><p><span>路透社倫敦/哥本哈根10月17日</span><span> - </span>諾和諾德<span>NOVOb.CO</span>在LinkedIn上發表聲明稱，已任命美國製藥業高管格雷格-麥利（Greg Miley）為其新任企業事務主管，因為這家肥胖症製藥商在藥品定價方面面臨着來自特朗普政府越來越大的壓力。</p><p>美國人麥利目前是美國製藥巨頭<a href=\"https://laohu8.com/S/ABBV\">艾伯維公司</a>（AbbVie <span>ABBV.N</span>）負責政府事務的高級副總裁。他週五在LinkedIn上發佈了這一聲明，諾和諾德公司與路透社分享了這一聲明。</p><p>(為便利非英文母語者，路透將其報導自動化翻譯為數種其他語言。由於自動化翻譯可能有誤，或未能包含所需語境，路透不保證自動化翻譯文本的準確性，僅是為了便利讀者而提供自動化翻譯。對於因為使用自動化翻譯功能而造成的任何損害或損失，路透不承擔任何責任。)</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0114720955.EUR","symbol_name":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251017:nL3T3VY13D:1","article_id":"2576679051","we_media_id":"1098195322","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2576679051","pubTimestamp":1760712438,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"路透中文","introduction":"路透中文","home_visible":1,"id":"1098195322","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"諾和諾德聘請美國製藥業資深人士，應對特朗普施加的定價壓力路透社倫敦/哥本哈根10月17日 - 諾和諾德NOVOb.CO在LinkedIn上發表聲明稱，已任命美國製藥業高管格雷格-麥利為其新任企業事務主管，因為這家肥胖症製藥商在藥品定價方面面臨着來自特朗普政府越來越大的壓力。他週五在LinkedIn上發佈了這一聲明，諾和諾德公司與路透社分享了這一聲明。對於因為使用自動化翻譯功能而造成的任何損害或損失，路透不承擔任何責任。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU0965509283.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (SGDHDG) INC","LU0234570918.USD":"高盛全球核心股票组合Acc Close","LU0432979614.USD":"JPM GLOBAL HEALTHCARE \"A\" ACC","IE00BGHQF631.EUR":"GUINNESS GLOBAL EQUITY INCOME \"C\" (EUR) ACC","LU0320765646.SGD":"FTIF - Franklin Income A MDIS SGD-H1","LU1839511570.USD":"WELLS FARGO GLOBAL FACTOR ENHANCED EQUITY \"I\" (USD) ACC","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","LU1718418525.SGD":"JPMorgan Investment Funds - Global Select Equity A (acc) SGD","LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS","IE00B3PB1722.GBP":"GUINNESS GLOBAL EQUITY INCOME \"C\" (GBP) INC","LU0708994859.HKD":"TEMPLETON GLOBAL \"A\" (HKD) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU2133065610.SGD":"JPMorgan Investment Funds - Global Dividend A (mth) SGD","IE00B42XCP33.USD":"GUINNESS GLOBAL EQUITY INCOME \"C\" (USD) INC","LU1551013342.USD":"Allianz Income and Growth Cl AMg2 DIS USD","LU0795875086.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD","LU1267930573.SGD":"TEMPLETON GLOBAL \"AA\" (SGD) ACC A","BK4588":"碎股","LU0029864427.USD":"TEMPLETON GLOBAL \"A\" (USD) INC","LU0882574055.USD":"富达全球健康医疗A ACC","BK4559":"巴菲特持仓","SG9999011175.SGD":"Nikko AM Global Dividend Equity Dis SGD-H","LU2129689514.USD":"FRANKLIN GLOBAL INCOME \"A\" (USD) INC","LU2089284900.SGD":"Allianz Global Sustainability Cl AM Dis H2-SGD","LU0861579265.USD":"联博低波幅策略股票基金A","LU0943347566.SGD":"安联收益及增长平衡基金AM H2-SGD","BK4550":"红杉资本持仓","LU0203347892.USD":"SCHRODER ISF QEP GLOBAL ACTIVE VALLUE \"A\" (USD)  INC AV","LU2129689431.USD":"FRANKLIN GLOBAL INCOME \"A\" (USD) ACC","LU0128525929.USD":"TEMPLETON GLOBAL \"A\" (USD) ACC","LU0234572021.USD":"高盛美国核心股票组合Acc","ABBV":"艾伯维公司","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","LU1244550577.SGD":"FTIF - Franklin Global Multi-Asset Income A (Mdis) SGD-H1","SG9999015945.SGD":"LionGlobal Disruptive Innovation Fund A SGD","LU0965509010.AUD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (AUDHDG) INC","LU2023251221.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"AM\" (USD) INC","LU1732800096.USD":"摩根大通环球收益基金A (irc)","LU0203345920.USD":"SCHRODER ISF QEP GLB ACT. VL \"A\" (USD) ACC","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","LU1496350171.SGD":"FRANKLIN DIVERSIFIED BALANCED \"A\" (SGDHDG) ACC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","LU0310800379.SGD":"FTIF - Templeton Global A Acc SGD","LU2237443465.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) INC","BK4585":"ETF&股票定投概念","LU1496350502.SGD":"FRANKLIN DIVERSIFIED DYNAMIC \"A\" (SGDHDG) ACC","LU0158827948.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"A\" (USD) INC"},"translate_title":"Novo Nordisk hires U.S. pharmaceutical industry veteran in response to pricing pressure exerted by Trump","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABBV":0.9},"content_text":"諾和諾德聘請美國製藥業資深人士，應對特朗普施加的定價壓力路透社倫敦/哥本哈根10月17日 - 諾和諾德NOVOb.CO在LinkedIn上發表聲明稱，已任命美國製藥業高管格雷格-麥利（Greg Miley）為其新任企業事務主管，因為這家肥胖症製藥商在藥品定價方面面臨着來自特朗普政府越來越大的壓力。美國人麥利目前是美國製藥巨頭艾伯維公司（AbbVie ABBV.N）負責政府事務的高級副總裁。他週五在LinkedIn上發佈了這一聲明，諾和諾德公司與路透社分享了這一聲明。(為便利非英文母語者，路透將其報導自動化翻譯為數種其他語言。由於自動化翻譯可能有誤，或未能包含所需語境，路透不保證自動化翻譯文本的準確性，僅是為了便利讀者而提供自動化翻譯。對於因為使用自動化翻譯功能而造成的任何損害或損失，路透不承擔任何責任。)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"executive","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}